Evaluation of Effectiveness of Conventional Chemotherapy in Patients with Acute Myeloid Leukaemia

Acute myeloid leukemia is the second most common type of leukemia in adults. The treatment of acute myeloid leukemia is very challenging. This observational study was conducted with total of 54 patients with de novo acute myeloid leukemia were identified at the department of Hematology in National Institute of Cancer Research and Hospital, Dhaka, Bangladesh from July 2016 to June 2022 who were treated with induction chemotherapy (3+7) consisting of daunorubicin and cytarabine and 3 cycles High dose intermittent ARA-Cas consolidation regimen. Patients who were refractory to induction therapy received re-induction therapy, if they achieved remission after re-induction then received consolidation therapy. Morphological complete remission was achieved in 70.4% of the patients and resistant disease was seen in 22.2% after induction therapy. Early mortality after induction therapy occurred in 7.4% cases. Thirty three percent (33.0%) of patients with complete remission after conventional therapy developed relapse with median follow up of 36 months. The median overall survival was 18 months. The overall survival of acute myeloid leukemia patients was 42.6% at 6 years. The event-free survival at a median of 36 months was 33.3%. With the view of scarcity of the indexed data in Bangladesh we have designed this study. In addition, this study result will help all hematologists.